Triple
T3205347
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | COVID-19 pandemic |
E67147
|
entity |
| Predicate | majorVaccineDeveloper |
P21964
|
FINISHED |
| Object |
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
|
E335285
|
NE FINISHED |
How this triple was built (5 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pfizer–BioNTech | Statement: [COVID-19 pandemic, majorVaccineDeveloper, Pfizer–BioNTech]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Pfizer–BioNTech Context triple: [COVID-19 pandemic, majorVaccineDeveloper, Pfizer–BioNTech]
-
A.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Pfizer
Pfizer is a major American multinational pharmaceutical and biotechnology corporation known for developing a wide range of prescription medicines and vaccines, including one of the first widely used COVID-19 vaccines.
-
D.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
E.
Janssen Biotech
Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Pfizer–BioNTech Triple: [COVID-19 pandemic, majorVaccineDeveloper, Pfizer–BioNTech]
Generated description
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Pfizer–BioNTech Target entity description: Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
-
A.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Pfizer
Pfizer is a major American multinational pharmaceutical and biotechnology corporation known for developing a wide range of prescription medicines and vaccines, including one of the first widely used COVID-19 vaccines.
-
D.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
E.
Janssen Biotech
Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
- F. None of above. chosen
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: majorVaccineDeveloper Context triple: [COVID-19 pandemic, majorVaccineDeveloper, Pfizer–BioNTech]
-
A.
majorDeveloper
chosen
Indicates that an entity is a primary or leading developer responsible for creating or significantly contributing to another entity.
-
B.
majorTradingCompany
Indicates that the subject is a principal or highly significant company engaged in large-scale trading activities with the object.
-
C.
majorShareholderOf
Indicates that one entity owns a controlling or significantly large portion of another entity’s shares or equity.
-
D.
isMajorCompanyIn
Indicates that a company is a leading or dominant business entity within a specified country, region, or market.
-
E.
memberCompany
Indicates that a company is formally part of, or affiliated as a member with, a larger organization, group, or association.
- F. None of above.
Provenance (6 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ad8589bd988190afa7ed2bdffb7b33 |
completed | March 8, 2026, 2:19 p.m. |
| NER | Named-entity recognition | batch_69adaa559848819082d1e61f586278dd |
completed | March 8, 2026, 4:56 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69b24bcbb0e88190b4413c4ba3de0eeb |
completed | March 12, 2026, 5:14 a.m. |
| NEDg | Description generation | batch_69b24ca05434819080ee515b1e7bdcb4 |
completed | March 12, 2026, 5:18 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69b24d19250c81908a9c3ac95b83a473 |
completed | March 12, 2026, 5:20 a.m. |
| PD | Predicate disambiguation | batch_69ad9e078f7c8190813d9fcb4f5071fb |
completed | March 8, 2026, 4:04 p.m. |
Created at: March 8, 2026, 3:07 p.m.